Michal Simicek
Overview
Explore the profile of Michal Simicek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magits W, Steklov M, Jang H, Sewduth R, Florentin A, Lechat B, et al.
EMBO J
. 2024 Jun;
43(14):2862-2877.
PMID: 38858602
The RAS pathway is among the most frequently activated signaling nodes in cancer. However, the mechanisms that alter RAS activity in human pathologies are not entirely understood. The most prevalent...
2.
Venglar O, Kapustova V, Sithara A, Zihala D, Muronova L, Sevcikova T, et al.
Br J Haematol
. 2023 Oct;
204(4):1439-1449.
PMID: 37807708
Induction therapy followed by CD34 cell mobilisation and autologous transplantation represents standard of care for multiple myeloma (MM). However, the anti-CD38 monoclonal antibodies daratumumab and isatuximab have been associated with...
3.
Sahinbegovic H, Vdovin A, Snaurova R, Durech M, Nezval J, Sobotka J, et al.
Curr Issues Mol Biol
. 2023 Aug;
45(8):6717-6727.
PMID: 37623244
Gene expression is a fundamental process that enables cells to produce specific proteins in a timely and spatially dependent manner. In eukaryotic cells, the complex organization of the cell body...
4.
Turi M, Sithara A, Hofmanova L, Zihala D, Radhakrishnan D, Vdovin A, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982699
During innate immune responses, myeloid differentiation primary response 88 (MyD88) functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family and...
5.
Celichowski P, Turi M, Charvatova S, Radhakrishnan D, Feizi N, Chyra Z, et al.
J Transl Med
. 2023 Mar;
21(1):197.
PMID: 36922828
Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chimeric antigen receptors (CARs)...
6.
Haertle L, Buenache N, Cuesta Hernandez H, Simicek M, Snaurova R, Rapado I, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672481
For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. Several underlying mechanisms have been proposed but...
7.
Snaurova R, Vdovin A, Durech M, Nezval J, Zihala D, Jelinek T, et al.
Mol Cell Biol
. 2022 Nov;
42(12):e0026522.
PMID: 36445135
OTUD1 is a deubiquitinating enzyme involved in many cellular processes including cancer and innate, immune signaling pathways. Here, we perform a proximity labeling-based interactome study that identifies OTUD1 largely present...
8.
Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, et al.
Nat Commun
. 2022 Nov;
13(1):6820.
PMID: 36357400
Serum monoclonal immunoglobulin (Ig) is the main diagnostic factor for patients with multiple myeloma (MM), however its prognostic potential remains unclear. On a large MM patient cohort (n = 4146),...
9.
Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Sithara A, Pospisilova L, et al.
J Clin Oncol
. 2022 Oct;
41(7):1383-1392.
PMID: 36315921
Purpose: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased...
10.
Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, et al.
Clin Cancer Res
. 2022 Oct;
29(1):279-288.
PMID: 36282272
Purpose: Proteasome inhibitors (PI) are the backbone of various treatment regimens in multiple myeloma. We recently described the first in-patient point mutations affecting the 20S subunit PSMB5 underlying PI resistance....